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INTRODUCTION 
Meningiomas are common brain tumours arising from meningeal tissue. Despite the 
majority of them displaying benign features, they can cause mild to severe morbidity. 
The current main therapeutic approach is complete tumour resection commonly with 
adjunct radiation therapy. However, tumour location can hamper complete resection 
and chemotherapies are ineffective. In this study we aim to elucidate dysregulated 
pathways in meningioma pathogenesis and identify novel molecular targets by 
deciphering the proteome and phosphoproteome of different grades of meningiomas. 
 
METHODS 
Tumour lysates were collected from grade I, II and III frozen meningioma specimens 
and three normal healthy human meninges. Phosphoprotein purification was 
performed using Qiagen® PhosphoProtein Purification Kit. Proteins were separated 
by SDS-PAGE followed by in-gel tryptic digestion. Extracted peptides were purified 
and analysed by electrospray ionization LC-MS/MS. Raw mass spectrometry files 
were analysed using MaxQuantTM. Expression data was validated by Western blot 






We have quantified 3888 proteins and 3074 phosphoproteins across all grades of 
meningioma and normal meninges. Comparative analysis confirmed 181 proteins 
and 338 phosphoproteins to be commonly significantly upregulated (log2 fold-
change≥1.5; p<0.05) among all grades vs. normal meninges. We have successfully 
validated the expression data of several upregulated proteins and phosphoproteins. 
Gene Ontology revealed biological processes including EFGR and VEGFR signalling 
to be enriched in the phosphoproteome. Grade-wise comparisons identified 667 
proteins and 769 phosphoproteins to be differentially expressed (p<0.05) between 
grade III meningiomas compared to grade II and I. 
 
CONCLUSION 
We have performed a comparative proteomic analysis across all meningioma grades 
and identified changes in proteomic profiles between these tumours and normal 
healthy meninges. We will use this data to define novel targets common to all grades 
and specific to a grade of meningioma for future therapies. 
 
